Your Daily Pharmaceuticals Briefing
Drug approvals, clinical trials, pricing debates, and the pharmaceutical industry landscape. Get the latest pharmaceuticals developments delivered to your inbox every morning. AI-powered, personalized, and grounded in real sources.
FDA Greenlights New Therapies Amidst Key Industry Shifts
The U.S. Food and Drug Administration (FDA) granted accelerated approval to atacicept (Trutakna; Vera Therapeutics) on July 7, 2026, for adults with IgA nephropathy, marking it as the first dual BAFF and APRIL inhibitor for this progressive kidney disease. Additionally, on July 9, 2026, the FDA approved isatuximab-irfc (Sarclisa Escena, Sanofi-Aventis U.S. LLC) for subcutaneous injection, expanding treatment options for multiple myeloma indications.
In a significant industry acquisition, Vertex Pharmaceuticals announced its largest deal to date, acquiring Crinetics Pharmaceuticals for $10 billion. This strategic move signals Vertex's intent to expand beyond its traditional focus on cystic fibrosis and diversify its therapeutic portfolio.
Pharmaceutical companies face a critical deadline of July 31, 2026, to finalize onshoring agreements with the Trump administration. These agreements are designed to reduce a looming tariff on branded pharmaceutical imports from 100% to 20%, with companies that have existing "most-favored-nation" drug pricing deals potentially avoiding the tariff entirely.
The Bottom Line
Recent FDA approvals are bringing novel mechanisms of action to market for serious conditions, while major M&A activity reshapes company portfolios. Simultaneously, the industry navigates significant policy pressures, including impending tariffs that could dramatically impact import costs and manufacturing strategies.
Get Pharmaceuticals in your inbox every morning
Join readers who start their day with an AI-powered briefing on pharmaceuticals and the topics they care about most — fully sourced and ready in 5 minutes.
Start your free trial7-day free trial · No credit card required
Related Briefings
Pick your topics
Pharmaceuticals, plus anything else you follow
We research overnight
AI synthesizes real-time sources while you sleep
Read in 5 minutes
Cited, structured, no fluff — in your inbox every morning